SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Person isolating in solitude separated behind a wall concept for being different, shyness, self isolation or individuality
Sickle cell disease
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
February 23, 2026
 · 
6 min read
 · 
Heather McKenzie
Human hands holding colorful pieces of puzzle. Vector hand drawn sketch illustration. Business team solving problem, joining and connecting jigsaw. Teamwork, partnership, business solution concept
MASH
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and combination treatments, that seek to mirror the commercial success of Madrigal’s Rezdiffra.
February 23, 2026
 · 
6 min read
 · 
Ben Hargreaves
Created with Canva Dreamlab †
FDA
Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump
Following the FDA’s refusal to review Moderna’s investigational mRNA flu vaccine last week, Commissioner Marty Makary faced questions from the U.S. president about the agency’s handling of vaccines. It’s a clear signal that the tension long brewing at the drug regulator has now gone all the way to the top.
February 20, 2026
 · 
7 min read
 · 
Heather McKenzie
protesters group silhouettes with american flag
Opinion
Policymakers Must Sustain American Life Sciences Leadership
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
February 20, 2026
 · 
4 min read
 · 
Dan Leonard
Man hand with magnifying glass. Yellow ray coming from loupe. Conducting check, information search and analysis concept. Spy, accountant, auditor job in abstract style. High quality photo
Regulatory
FDA’s Top Drug Regulator To Probe Safety of Antidepressants, RSV Antibodies
Tracy Beth Høeg addressed FDA staffers for the first time in her role as the fifth CDER chief under President Donald Trump, announcing inquiries into the use of SSRIs in pregnancy and RSV antibodies in infants despite well-documented safety of these treatments.
February 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
February 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Pictured: J&J's office in Madrid, Spain
Manufacturing
J&J Plans $1B Investment in PA Cell Therapy Manufacturing Facility
Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.
February 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Collage with colorful casino chips cards dices representing online gambling poker betting e-gaming entertainment.
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
February 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Black box mockup for cosmetics, perfume, presentation with shadows, isolated on background. Product photo for advertising package. Template for stylish cardboard packaging for goods.
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
The FDA’s drug review process can often be “unpredictable,” and review teams typically “differ greatly” in what they ask of drug sponsors, Sen. Bill Cassidy said.
February 19, 2026
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS